Objective
This trial is no longer accepting applications.
For questions related to the trial, please contact Bing Chen at 312.238.7895.
This study is examining how the study drug, NVG-291, affects nerve connections in the spinal cord and whether it is safe and tolerable to use.
Volunteers in this study will:
- Participate in study visits over 16 weeks.
- Visits will take place at the Shirley Ryan AbilityLab.
Visit involves:
- Non-invasive stimulation of the brain and spinal cord and startle acoustic stimuli.
- Upper and lower limb training
- Answer questionnaire
- Physiological and physical assessments
- Receiving daily injections of NVG-291 or placebo.
Who Can Participate
Participants with a spinal cord injury who are:
- Between 18-75 years of age
- Sustained a spinal cord injury at C1-C7 (20-90 days post injury)
- In good physical health
- Proficiency in English
Compensation
Participants will receive compensation.
